vascuCAP vs Viz HCM
Similar category, different focus. These tools serve overlapping but distinct needs.
Comparability 60/100
Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
AI Verdict
While both vascuCAP and Viz HCM are FDA-cleared AI tools for cardiology and clinical decision support, they address distinct clinical problems. vascuCAP focuses on quantifying plaque composition from CT angiography to assess general cardiovascular risk, whereas Viz HCM specializes in detecting Hypertrophic Cardiomyopathy (HCM) using real-time ECG analysis and coordinating care for this specific condition.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Frequently Asked Questions
vascuCAP (now ElucidVivo/PlaqueIQ) is designed for non-invasive CT angiography analysis, quantifying plaque composition and assessing cardiovascular risk for conditions like stroke and heart attack. Viz HCM, in contrast, uses real-time ECG analysis to detect suspected Hypertrophic Cardiomyopathy (HCM) and coordinate cardiac care.
vascuCAP analyzes non-invasive CT angiogram images to characterize arterial plaque. Viz HCM performs AI-powered analysis on electrocardiograms (ECGs) for real-time detection of suspected HCM.
vascuCAP provides histologically-validated plaque quantification and characterization, including lipid-rich necrotic core, calcification, and intraplaque hemorrhage, along with 3D visualization and risk stratification. Viz HCM offers real-time detection of suspected HCM from ECGs, mobile-based alerts, and automated direction of patients to appropriate care specialists.
vascuCAP is primarily intended for Cardiology, Radiology, and Vascular Surgery, supporting personalized treatment decisions based on plaque assessment. Viz HCM targets Cardiology, Emergency Medicine, and Hospital Medicine for rapid HCM detection and streamlined care coordination.
For Viz HCM, CMS reimbursement is available for CPT codes 0764T and 0765T, with a national payment rate of $128.90 effective January 1, 2025. For Elucid Bioimaging's Plaque-IQ (formerly vascuCAP), a new Category I CPT code 75577 for quantitative coronary plaque analysis became effective January 1, 2026, with a national average payment amount of $1,012 for imaging centers and physician offices, and $951 for hospital outpatient settings.